NEW YORK (GenomeWeb News) – Illumina said this week that its board has authorized the repurchase of up to $250 million of the company's common stock. The new repurchase program is in addition to Illumina's current program, which has $117.5 million available for share repurchases.

The US Food and Drug Administration confirmed by notice in the Federal Register that its Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee will review Exact Sciences' premarket approval application for the Cologuard colorectal screening test on March 27.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.